ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- The eligibility table has been updated to indicate that residents of long term care (LTC), alternate level of care clients awaiting placement in LTC, individuals 70 years of age and older, and indigenous persons 55 years of age and older are eligible for a second booster dose at least 6 months after the first booster dose. See the BOOSTER DOSE section of the respective COVID-19 vaccine product pages for more information.
- AstraZeneca COVID-19 vaccine has been removed from the eligibility list as it is not currently available in BC.

Please remove page numbers: 1-2 dated March 18, 2022
Please add new page numbers: 1-2 dated April 4, 2022

The following COVID-19 vaccine product pages have been updated to indicate the following:

A second booster dose of a COVID-19 mRNA vaccine should be offered to the following individuals at least 6 months after the first booster dose (minimum interval of 4 months):

- Residents of LTC and alternate level of care clients awaiting placement in LTC
- Residents of assisted living facilities 70 years of age and older (Indigenous persons 55 years of age and older)
- Individuals 80 years of age and older in the community

A second booster dose of a COVID-19 mRNA vaccine may be offered to the following individuals at least 6 months after the first booster dose (minimum interval of 4 months):

- Individuals 70-79 years of age in the community
- Indigenous persons 55-79 years of age in the community
COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

Please remove page numbers: 1-6 dated March 18, 2022
Please add new page numbers: 1-7 dated April 4, 2022

COVID-19 Vaccine SPIKEVAX™ (Moderna)

NOTE: The dosage for the second booster dose of Moderna COVID-19 vaccine is 0.25 mL (50 mcg) regardless of age or setting.

Please remove page numbers: 1-6 dated March 18, 2022
Please add new page numbers: 1-6 dated April 4, 2022

COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

Please remove page numbers: 1-4 dated February 25, 2022
Please add new page numbers: 1-5 dated April 4, 2022

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

Please remove page numbers: 1-4 dated February 25, 2022
Please add new page numbers: 1-5 dated April 4, 2022

COVID-19 Vaccine Nuvaxovid™ (Novavax)

Please remove page numbers: 1-3 dated March 4, 2022
Please add new page numbers: 1-3 dated April 4, 2022
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong
Executive Director, Public Health, Planning and Prevention, Population and Public Health Division